Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · U.S. Code · Title 42 - THE PUBLIC HEALTH AND WELFARE · CHAPTER 6A— PUBLIC HEALTH SERVICE · Part B— Research Authority · § 300cc–17

§ 300cc–17. Information services

758 words·~3 min read·/usc/title-42/section-300cc-17

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

The Secretary shall establish, maintain, and operate a program with respect to information on research, treatment, and prevention activities relating to infection with the etiologic agent for acquired immune deficiency syndrome. The program shall, with respect to the agencies of the Department of Health and Human Services, be integrated and coordinated. After consultation with the Director of the Office of AIDS Research, the Administrator of the Health Resources and Services Administration, and the Director of the Centers for Disease Control and Prevention, the Secretary shall provide for toll-free telephone communications to provide medical and technical information with respect to acquired immune deficiency syndrome to health care professionals, allied health care providers, and to professionals providing emergency health services.
Information provided pursuant to paragraph
(1)shall include— information on prevention of exposure to, and the transmission of, the etiologic agent for acquired immune deficiency syndrome; and information contained in the data banks established in subsections
(c)and (d). After consultation with the Director of the Office of AIDS Research, the Director of the Centers for Disease Control and Prevention, and the National Library of Medicine, the Secretary shall establish a data bank of information on the results of research with respect to acquired immune deficiency syndrome conducted in the United States and other countries. In carrying out paragraph (1), the Secretary shall collect, catalog, store, and disseminate the information described in such paragraph. To the extent practicable, the Secretary shall make such information available to researchers, physicians, and other appropriate individuals, of countries other than the United States. After consultation with the Commissioner of Food and Drugs, the AIDS Research Advisory Committee established under section 300cc–3 of this title , and the Director of the Office of AIDS Research, the Secretary shall, in carrying out subsection (a), establish a data bank of information on clinical trials and treatments with respect to infection with the etiologic agent for acquired immune deficiency syndrome (hereafter in this section referred to as the “Data Bank”). In carrying out paragraph (1), the Secretary shall collect, catalog, store, and disseminate the information described in such paragraph. The Secretary shall disseminate such information through information systems available to individuals infected with the etiologic agent for acquired immune deficiency syndrome, to other members of the public, to health care providers, and to researchers. The Data Bank shall include the following: A registry of clinical trials of experimental treatments for acquired immune deficiency syndrome and related illnesses conducted under regulations promulgated pursuant to section 355 of title 21 that provides a description of the purpose of each experimental drug protocol either with the consent of the protocol sponsor, or when a trial to test efficacy begins. Information provided shall include eligibility criteria and the location of trial sites, and must be forwarded to the Data Bank by the sponsor of the trial not later than 21 days after the approval by the Food and Drug Administration. Information pertaining to experimental treatments for acquired immune deficiency syndrome that may be available under a treatment investigational new drug application that has been submitted to the Food and Drug Administration pursuant to part 312 of title 21, Code of Federal Regulations. The Data Bank shall also include information pertaining to the results of clinical trials of such treatments, with the consent of the sponsor, of such experimental treatments, including information concerning potential toxicities or adverse effects associated with the use or administration of such experimental treatment. ( July 1, 1944, ch. 373 , title XXIII, § 2317, as added Pub. L. 100–607, title II, § 201(4) , Nov. 4, 1988 , 102 Stat. 3071 ; amended Pub. L. 100–690, title II, § 2617(c) , Nov. 18, 1988 , 102 Stat. 4240 ; Pub. L. 102–531, title III, § 312(d)(19) , Oct. 27, 1992 , 106 Stat. 3505 ; Pub. L. 103–43, title XX, § 2008(d)(4) , June 10, 1993 , 107 Stat. 212 .)
Connections8 off-index
8 references not yet in our index
  • Pub. L. 100-607
  • 102 Stat. 3071
  • Pub. L. 100-690
  • 102 Stat. 4240
  • Pub. L. 102-531
  • 106 Stat. 3505
  • Pub. L. 103-43
  • 107 Stat. 212
Citation graph
cites case law
§ 300cc–17
Information services
Pub. L.Pub. L. 100-607
Stat.102 Stat. 3071
Pub. L.Pub. L. 100-690
Stat.102 Stat. 4240
Pub. L.Pub. L. 102-531
Cites 8 · showing 5Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.